目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T25322 | Others | ||
Diazoketone methotrexate is an analog of methotrexate with potential antitumor activity. | |||
T10658 | HIV Protease | ||
CA inhibitor 1 (GS-6207 analog) is a potent inhibitor of the HIV capsid. | |||
T84939 | Others | ||
Metformin hydroxy analog 2, an oxidation product of the biguanide metformin (1), represents a chemically transformed variant of the original compound, showcasing a modified molecular structure through the process of oxidation. | |||
T84713 | Others | ||
Deruxtecananalog 2 (monoTFA),作为Deruxtecan的同系物,是DX-8951衍生物(Dxd)和ADC Linker偶联而成的ADC毒素。 | |||
T84442 | Others | ||
MCHB-1, a potent agonist of the human cannabinoid 2 (CB2) receptor (EC50= 0.52 nM), demonstrates high selectivity for CB2 over CB1 (Kis = 3.7 and 110 nM, respectively), distinguishing itself from similar benzimidazole compounds that significantly alleviate peripheral pain while minimizing central nervous system side effects in mice. | |||
T81825 | |||
[Leu27]-Melan-A, MART-1 (26-35)是一种具有改良的HLA-A*0201结合能力和增强的免疫原性及抗原性的生物活性肽。该类似物在第27位的Leu替换了Ala,与原生Melan-A (26-35)相比表现出更佳的性能。当序列N端为谷氨酰胺(Q)或谷氨酸(E)时,肽可能会自发形成焦谷氨酰(pGlu)。Q或E到pGlu的转化是自然发生的,pGlu的疏水性γ-内酰胺环被认为可增强针对胃肠道蛋白酶的抵抗力,使得含pGlu的肽成为这类肽的正常子集,在HPLC分析中通常作为评估肽纯度的一部分。 | |||
T64414 | Wnt/beta-catenin | ||
PRI-724 (C-82 prodrug)是β-catenin/CBP 相互作用的选择性小分子抑制剂。 | |||
T31772 | Others | ||
Fenitrooxone is a bio-active chemical. Detailed information has not been published. | |||
T17115 | Others | ||
Tolycaine 是一种局部麻醉剂。 | |||
T13429 | Others | ||
α-2,3-sialyltransferase-IN-1 is a noncompetitive inhibitor of α-2,3-sialyltransferase(IC50 of 6 μM). |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-03036 | Cytotoxin 2 Protein, Naja atra, Recombinant (His & Myc) | Naja atra | E. coli | ||
Basic protein that binds to cell membrane and depolarizes cardiomyocytes. It also shows lytic activities, but 2-fold less important than that of CTX-A4. It binds to the integrin alpha-V/beta-3 (ITGAV/ITGB3) with a moderate affinity. It may interact with sulfatides in the cell membrane which induces pore formation and cell internalization and is responsible for cytotoxicity in cardiomyocytes. It also may target the mitochondrial membrane and induce mitochondrial swelling and fragmentation.
|
|||||
TMPH-00645 | Lactose permease Protein, E. coli, Recombinant (His) | E. coli | E. coli | ||
Responsible for transport of beta-galactosides into the cell, with the concomitant import of a proton (symport system). Can transport lactose, melibiose, lactulose or the analog methyl-1-thio-beta,D-galactopyranoside (TMG), but not sucrose or fructose. The substrate specificity is directed toward the galactopyranosyl moiety of the substrate. Lactose permease Protein, E. coli, Recombinant (His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 34.4 kDa and the accession number is P02920.
|
|||||
TMPJ-00871 | BAR Protein, S. hygroscopicus, Recombinant | Streptomyces hygroscopicus | E. coli | ||
Phosphinothricin N-acetyltransferase (PAT) is an enzyme that acetylates the free NH2 group of L-phosphinothricin (L-PPT) in the presence of acetyl-CoA as a co-substrate. It is highly specific for L-PPT and does not acetylate other L-amino acids or structurally similar molecules. L-PPT is a glutamate analog that can inhibit glutamine synthetase activity in plants, resulting in the accumulation of ammonia to toxic levels and impairment of photosynthesis. The introduction of a PAT gene into a plant genome can confer resistance to glufosinate herbicide during post-emergent applications.
|
|||||
TMPH-03038 | Cobra venom factor Protein, Naja kaouthia, Recombinant (His & SUMO) | Naja kaouthia | E. coli | ||
Complement-activating protein in cobra venom. It is a structural and functional analog of complement component C3b, the activated form of C3. It binds factor B (CFB), which is subsequently cleaved by factor D (CFD) to form the bimolecular complex CVF/Bb. CVF/Bb is a C3/C5 convertase that cleaves both complement components C3 and C5. Structurally, it resembles the C3b degradation product C3c, which is not able to form a C3/C5 convertase. Unlike C3b/Bb, CVF/Bb is a stable complex and completely resistant to the actions of complement regulatory factors H (CFH) and I (CFI). Therefore, CVF continuously activates complement resulting in the depletion of complement activity.
|